S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

JOURNAL ARTICLE published March 2018 in Annals of Oncology

Authors: Y. Yamada | T. Denda | M. Gamoh | I. Iwanaga | S. Yuki | H. Shimodaira | M. Nakamura | T. Yamaguchi | H. Ohori | K. Kobayashi | M. Tsuda | Y. Kobayashi | Y. Miyamoto | M. Kotake | K. Shimada | A. Sato | S. Morita | S. Takahashi | Y. Komatsu | C. Ishioka